Stockreport

Protalix out-licenses Fabry candidate PRX-102 to Chiesi; shares ahead 38% premarket [Seeking Alpha]

Protalix BioTherapeutics, Inc. (DE)  (PLX) 
PDF Protalix out-licenses Fabry candidate PRX-102 to Chiesi; shares ahead 38% premarketNano cap Protalix BioTherapeutics (NYSEMKT:PLX) jumps38% premarket on robust volume in [Read more]